证券代码：300451 证券简称：创业慧康 公告编号：2025-075 创业慧康科技股份有限公司 关于持股 5%以上股东提前终止减持计划的公告 持股 5%以上股东葛航先生保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 持股 5%以上股东葛航先生于 2025 年 9 月 24 日披露了《关于持股 5%以上 股东减持股份预披露公告》（公告编号：2025-051），持股 5%以上股东葛航先 生计划自上述公告之日起十五个交易日后的 3 个月内（2025 年 10 月 23 日至 2026 年 1 月 22 日）以集中竞价方式和大宗交易方式合计减持创业慧康科技股份有限 公司（以下简称"公司"）股份不超过 37,038,029 股（含），占公司总股本比例 2.3909%。 近日，公司收到葛航先生出具的《关于终止减持计划的告知函》，葛航先生 与杭州更好智投管理咨询合伙企业(有限合伙)(以下简称"杭州更好")于近期签 署了《股份转让协议》和《表决权委托暨一致行动协议》，约定由葛航先生通过 协议转让方式向杭州更好转让公司 96,52 ...

公告显示，葛航原计划以集中竞价方式和大宗交易方式合计减持创业慧康股份不超过3703.8万股 （含），占公司总股本比例2.3909%。截至11月27日，葛航持有公司1.56亿股，占公司总股本的 10.06%，未实施任何减持操作。 北京商报讯（记者 丁宁）11月27日晚间，创业慧康（300451）发布公告称，近日，公司收到葛航出具 的《关于终止减持计划的告知函》，葛航与杭州更好智投管理咨询合伙企业(有限合伙)(以下简称"杭州 更好")于近期签署了《股份转让协议》和《表决权委托暨一致行动协议》，约定由葛航通过协议转让方 式向杭州更好转让公司9652.51万股股份(约占公司总股本的6.23%)。同时，葛航将所持有的公司1.56亿 股股份(约占公司总股本的10.06%）的表决权全权委托予杭州更好行使。签署上述协议后，葛航与杭州 更好形成一致行动人关系。基于上述情况，葛航决定提前终止本次减持计划。 ...

Core Viewpoint - The leading medical information technology company, Chuangye Huikang, is set to change ownership as Hangzhou Genghao Investment Management Partnership has initiated a share transfer process, marking a significant shift in control amidst declining performance for both companies [1][8]. Group 1: Ownership Change - Hangzhou Genghao has paid approximately 158 million yuan as the first installment for the share transfer [1]. - The agreement involves Hangzhou Genghao acquiring 9,652,509 shares from the largest shareholder, Ge Hang, representing 6.23% of the total share capital, at a price of 5.18 yuan per share, totaling 500 million yuan [3][4]. - Following the transfer, Hangzhou Genghao's voting rights will increase from 0% to 12.64%, making it the largest shareholder of Chuangye Huikang [4]. Group 2: Financial Performance - Chuangye Huikang has experienced three consecutive years of declining performance, with a reported net loss of 173 million yuan in 2024, marking its first loss since going public [9]. - For the first three quarters of 2025, the company reported a revenue of 862 million yuan, a decrease of 26.26% year-on-year, and a net loss of 122 million yuan, a staggering decline of 331.69% [10]. - Hangzhou Genghao's parent company, Huajian Medical, also reported a decline in performance, with a revenue of 1.27 billion yuan in the first half of 2025, down 6.2%, and a net profit of 38.32 million yuan, down 70% [7][8]. Group 3: Strategic Intent - The acquisition aims to position Chuangye Huikang as a leader in the AI healthcare sector, with plans for board restructuring and potential capital increases to enhance control [5][8]. - Chuangye Huikang, founded in 1997, focuses on medical information services and has seen its market value drop significantly from over 20 billion yuan at its peak [8][10].

证券日报网讯创业慧康11月26日在互动平台回答投资者提问时表示，公司第三季度末股东总数为64387 户。 （文章来源：证券日报） ...

Core Viewpoint - The stock of Chuangye Huikang (300451) has shown a recent increase in price, but the company is facing significant financial challenges, including declining revenues and net profits [1][3]. Financial Performance - As of November 25, 2025, Chuangye Huikang's stock closed at 5.43 yuan, up 3.23% with a trading volume of 978,900 shares and a total transaction value of 535 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 862 million yuan, a year-on-year decrease of 26.26%, and the net profit attributable to shareholders was -122 million yuan, down 331.69% [3]. - In Q3 2025 alone, the company reported a main revenue of 285 million yuan, a decline of 35.5% year-on-year, and a net profit of -41.67 million yuan, down 264.2% [3]. Market Position and Ratios - Chuangye Huikang's total market value is 8.412 billion yuan, which is below the software development industry average of 12.944 billion yuan, ranking 79th out of 195 companies [3]. - The company's price-to-earnings ratio (P/E) is -51.62, while the industry average is 126.72, indicating a significant underperformance [3]. - The gross profit margin stands at 49.87%, higher than the industry average of 43.84%, ranking 73rd in the industry [3]. Investment Sentiment - In the last 90 days, three institutions have rated the stock as a buy, with an average target price of 5.76 yuan [4].

Market Overview - As of 10:31 AM today, the Shanghai Composite Index is at 3876.57 points, above the six-month moving average, with an increase of 1.04% [1] - The total trading volume of A-shares today is 853.41 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 382 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Tonghe Technology (300491) with a deviation rate of 9.12% and a price increase of 10.01% [1] - Xunxing Co., Ltd. (002098) with a deviation rate of 9.03% and a price increase of 10.04% [1] - Laimu Co., Ltd. (603633) with a deviation rate of 7.04% and a price increase of 7.90% [1] Additional Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Longyuan Technology (not specified) and Newcapec (not specified) with minor deviations [1] - Other stocks with notable performance include: - Hongbai New Materials (605366) with a deviation rate of 6.77% and a price increase of 7.26% [1] - Kecuan Technology (603052) with a deviation rate of 5.50% and a price increase of 10.00% [1]

Core Viewpoint - The control change plan of Chuangye Huikang (300451.SZ) has emerged, with founder Ge Hang transferring the largest shareholder position to Hangzhou Genghao Investment Management Partnership (Limited Partnership) for 500 million yuan, aiming to restructure the board and gain actual control [1][2]. Group 1: Control Change Details - The control change involves a "transfer agreement + voting rights entrustment" approach, where Ge Hang will transfer 96.52 million shares (6.23% of total shares) to Hangzhou Genghao at a price of 5.18 yuan per share, totaling 500 million yuan [2]. - After the transfer, Hangzhou Genghao will control 12.64% of the voting rights through entrusted voting rights, becoming the largest shareholder of Chuangye Huikang [2][3]. - The board will be restructured to include four non-independent directors and two independent directors nominated by Hangzhou Genghao, resulting in a total of 11 board members [2]. Group 2: Financial and Operational Challenges - Chuangye Huikang is facing significant financial difficulties, with a revenue decline of 26.26% year-on-year to 862 million yuan in the first nine months of 2025, and a net profit drop of 331.69% to -122 million yuan [9][10]. - The company has accumulated 1.643 billion yuan in accounts receivable, nearly double its revenue, which is straining cash flow and operational efficiency [10]. - The company has been consistently recognizing credit impairment and asset impairment provisions, with significant amounts recorded in the first three quarters of 2025 [10]. Group 3: Strategic Intentions and Market Outlook - Hangzhou Genghao aims to leverage the acquisition to achieve financial consolidation and accelerate business development, capitalizing on the growing "AI + healthcare" market [7][9]. - Despite the operational challenges, Chuangye Huikang's stock price has shown an upward trend since the announcement of the control change, indicating market optimism about potential recovery through the acquisition [11].

证券代码：300451 证券简称：创业慧康 公告编号：2025-074 创业慧康科技股份有限公司 关于筹划控制权变更事项进展的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次筹划控制权变更事项的情况 2025 年 11 月 12 日，杭州更好智投管理咨询合伙企业（有限合伙）（以下 简称"杭州更好"或"更好智投"）与公司第一大股东、持股 5%以上股东葛航 先生签署了《股份转让协议》，约定葛航将通过协议转让的方式向杭州更好转让 公司 96,525,096 股股份（约占公司总股本的 6.23%），每股转让价格为人民币 5.18 元（"协议转让"），不低于公司前一交易日（2025 年 11 月 7 日）股票收盘价 的 80%；同日，杭州更好与葛航先生签署了《关于创业慧康科技股份有限公司的 表决权委托暨一致行动协议》，约定葛航将持有的公司 155,780,282 股（约占公 司总股本的 10.06%，含协议转让对应的 96,525,096 股股份）股份表决权全权委 托给杭州更好行使。上述协议签署后，杭州更好与葛航形成一致行动人关系。2025 年 11 月 14 ...

Group 1 - The core viewpoint of the news is that Chuangye Huikang's stock experienced a decline of 4.04% on November 20, with a trading volume of 350 million yuan, indicating a significant market reaction [1] - On November 20, Chuangye Huikang had a financing buy-in amount of 37.60 million yuan and a net financing buy of 8.33 million yuan, with a total financing and margin balance of 532 million yuan [1] - The financing balance of Chuangye Huikang is 531 million yuan, accounting for 6.56% of its circulating market value, which is above the 60th percentile level over the past year, indicating a high level of financing activity [1] Group 2 - Chuangye Huikang, established on December 10, 1997, and listed on May 14, 2015, operates in the healthcare information technology sector, with main business activities including software sales and system integration [2] - For the period from January to September 2025, Chuangye Huikang reported a revenue of 862 million yuan, a year-on-year decrease of 26.26%, and a net profit attributable to shareholders of -122 million yuan, a significant decline of 331.69% [2] - As of September 30, 2025, the number of shareholders of Chuangye Huikang was 64,400, a decrease of 0.69% from the previous period, while the average circulating shares per person increased by 0.70% to 23,711 shares [2] Group 3 - Chuangye Huikang has distributed a total of 230 million yuan in dividends since its A-share listing, with cumulative distributions of 30.94 million yuan over the past three years [3] - As of September 30, 2025, among the top ten circulating shareholders, Noan Active Return Mixed A held 16.10 million shares, a decrease of 8.03 million shares from the previous period [3] - Hong Kong Central Clearing Limited and Guorong Rongsheng Longtou Selected Mixed A have exited the list of the top ten circulating shareholders, indicating changes in institutional holdings [3]

Group 1 - The core viewpoint of the news is that Chuangyue Huikang (300451) has been added to the "Alibaba" concept due to its collaborations with Alibaba, Tencent, and related companies in areas such as cloud computing and mobile payments within smart healthcare [1] - The company has other associated concept sectors including AI healthcare, DeepSeek, AI agents, AIGC, data elements, artificial intelligence, Huawei Harmony, Huawei computing power, smart healthcare, Xinchuang, blockchain, family doctors, Internet of Things, DRG-DIP, domestic software, big data, and elderly care [1] - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations, including smart medical health, Internet healthcare, medical IoT, health big data, smart healthcare solutions, system construction and operation, and innovative operational services [1] Group 2 - For the first three quarters of 2025, Chuangyue Huikang reported a main revenue of 862 million yuan, a year-on-year decrease of 26.26% [2] - The company's net profit attributable to shareholders was -122 million yuan, a year-on-year decline of 331.69%, while the non-recurring net profit was -142 million yuan, down 382.12% [2] - In the third quarter of 2025, the company recorded a single-quarter main revenue of 285 million yuan, a year-on-year decrease of 35.5%, with a net profit attributable to shareholders of -41.67 million yuan, down 264.2% [2] - The company's debt ratio stands at 20.27%, with investment income of 4.44 million yuan, financial expenses of -5.32 million yuan, and a gross profit margin of 49.87% [2]